- Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
- Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
- Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Autolus Therapeutics Announces Changes to its Board of Directors
- Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
- Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
- Autolus Therapeutics announces publication in Blood Cancer Journal
- Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
- Autolus Therapeutics announces publication in Nature Communications
- Autolus Announces Pricing of Underwritten Offering
More ▼
Key statistics
On Friday, Autolus Therapeutics PLC (6A3A:MUN) closed at 3.90, 156.58% above the 52 week low of 1.52 set on Apr 27, 2023.
52-week range
Open | 3.90 |
---|---|
High | 3.90 |
Low | 3.90 |
Bid | 3.72 |
Offer | 3.80 |
Previous close | 4.02 |
Average volume | 45.00 |
---|---|
Shares outstanding | 265.93m |
Free float | 8.82m |
P/E (TTM) | -- |
Market cap | 1.06bn USD |
EPS (TTM) | -1.20 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 07:03 BST.
More ▼